Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Carcinoma, Small Cell 1

Interventions

Cyclophosphamide 282Rituximab 260Etoposide 161Filgrastim 155Vincristine 145Doxorubicin 134Prednisone 117Cytarabine 108Radiotherapy 102Peripheral Blood Stem Cell Transplantation 90Methotrexate 90fludarabine phosphate 87Melphalan 78Busulfan 71Dexamethasone 59Granulocyte Colony-Stimulating Factor 56Carmustine 53fludarabine 51Bortezomib 46Tacrolimus 44Mycophenolic Acid 41Antilymphocyte Serum 41Ifosfamide 40Leucovorin 39Gemcitabine 38Whole-Body Irradiation 36Cyclosporine 35Bendamustine Hydrochloride 34sargramostim 33Methylprednisolone 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma × taxane × Clear all
NCT00044551 2013-10-14

Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

Bayer

Phase 2 Completed
29 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡